The first 5 pages of each search result were filtered on the assumption that the user would not go beyond the first 5 pages of the search result. We searched for combinations of search terms related to valproic acid (i.e., “Valproic Acid”, “Valproate”, “Depakene” and “Depakote”) and pregnancy (i.e., “pregnancy” and “gestation”), according to Mesh (Medical Subject Headings, MeSH). The method used was a systematic search via YouTube™ ( ) on January 16, 2023, for videos containing information about valproic acid use during pregnancy. Therefore, this study aims to systematically evaluate the usefulness of YouTube™ videos in the prevention of valproic acid use in women during pregnancy in order to improve the professionalism of the video site.īecause this study involved only the use of public access data, it was exempt from Institutional Review Board’s approval of the study site. To our knowledge, no previous studies have investigated the use of YouTube™ as a source of video education for the prevention of valproic acid use in women during pregnancy. Therefore, it is crucial to assess the quality of the information delivered. However, the freedom of anyone to post videos has led to a mix of video content and a lack of professional review. YouTube™, now recognized as one of the world’s most popular video sites, is increasingly being used as a platform for spreading health messages. In fact, videos could be an effective tool for raising patient awareness, as it can provide information in a visual way, which could overcome some of the barriers to health literacy. People are increasingly getting their health knowledge from the Internet, and people can easily and quickly search for the health information they want to know. Specifically, for female patients of fertile age, access to more information could increase their awareness and thus make the prevention of valproic acid use during pregnancy easier to implement. Dissemination of high-quality information about valproic acid teratogenesis via social media may be a potential tool for educating physicians and general users interested in the topic. But the use of valproic acid during pregnancy, which causes congenital malformations in infants, is a raw topic for people with or without a medical background. The European Medicines Agency officially recommended in 2018 that valproate not be used by women during their reproductive years without a systematic method of contraception. In addition to teratogenic effects, the use of valproate during pregnancy has been associated with cognitive and behavioral impairment in infants. The study by Jäger-Roman E and Martínez-Frías ML also shows that the use of valproic acid during pregnancy causes major malformations in infants with a large number of typical minor craniofacial and finger malformations. Subsequent studies have confirmed this increased risk and have also shown an increased risk of other major congenital malformations, including congenital malformations such as neural tube defects, atrial septal defects, and hypospadias in the fetus. In the 1980s, valproic acid monotherapy during the first trimester of pregnancy was first associated with an increased risk of congenital spina bifida. Although valproic acid proved to be a relatively safe drug, its side effects were quickly recognized. Valproic acid is currently used clinically for the treatment of epilepsy and bipolar disorder. Thanks to its large spectrum of activity, its use has expanded to the treatment of other types of mental disorders, either alone or as an adjunct to other medications. Valproic acid, a simple eight-carbon branched chain fatty acid, was initially used for seizure suppression. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |